Lapatinib

證據等級: L5

預測適應症: 1 個

Lapatinib: From HER2-Overexpressing Breast Cancer to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor originally used for HER2-overexpressing breast cancer. The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying mechanistic rationale is weak.

Quick Overview

Item	Content
Original Indication	HER2-overexpressing breast cancer (derived from repurposing rationale text; not confirmed by formal regulatory/label data)
Predicted New Indication	Dermatofibrosarcoma Protuberans
TxGNN Prediction Score	99.30%
Evidence Level	L5 (model prediction only, no clinical trials or literature)
Germany Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data (MOA) is not available in structured form. Based on the evidence pack's rationale text, lapatinib is a dual EGFR/HER2 (ErbB1/ErbB2) tyrosine kinase inhibitor, primarily used for HER2-overexpressing breast cancer.

However, the biological link between this MOA and DFSP is weak. DFSP is driven predominantly by the COL1A1-PDGFB fusion gene, which causes constitutive activation of PDGFRB — a pathway targeted by imatinib (a PDGFR inhibitor), not by EGFR/HER2 inhibitors. There is currently no known literature demonstrating clinically meaningful EGFR or HER2 overexpression or driver mutations in DFSP tumor cells.

This prediction should therefore be interpreted as a TxGNN knowledge-graph association only, lacking independent biological plausibility support at this stage, and should be treated with a high degree of skepticism.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Lapatinib is currently not marketed in Germany under this evidence pack (0 authorizations found); no product/dosage form/indication data is available.

Cytotoxicity

Lapatinib is an antineoplastic agent (breast cancer indication), classified as a targeted therapy rather than a conventional cytotoxic agent.

Item	Content
Cytotoxicity Classification	Targeted therapy (dual EGFR/HER2 tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/BfArM label warnings and contraindications are currently unavailable — this is flagged as a Blocking data gap and must be resolved before any safety review can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a TxGNN model score (L5, no clinical trials or literature), the proposed mechanism does not align with the known driver pathway of DFSP (COL1A1-PDGFB/PDGFRB, not EGFR/HER2), and the drug is not currently marketed in Germany. In addition, TFDA label safety data (warnings/contraindications) is missing, which is a blocking gap for any safety evaluation.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — Blocking gap, required before S1 safety review
Confirmed original MOA and indication data from DrugBank/regulatory source
Preclinical evidence of EGFR/HER2 relevance in DFSP tumor biology, if any exists
Clinical trial or case-report evidence specifically evaluating lapatinib in DFSP or PDGFR-driven sarcomas
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.